Press Releases

Eisai Inc. Divests U.S. Rights for GLIADEL® Wafer (polifeprosan 20 with carmustine implant) to Arbor Pharmaceuticals

December 17, 2012

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced that it has entered into a definitive asset purchase agreement to divest U.S. rights for Gliadel® Wafer (polifeprosan 20 with carmustine implant) to specialty pharmaceutical company Arbor Pharmaceuticals, Inc.

Read More